339 related articles for article (PubMed ID: 33300952)
1. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
2. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
[TBL] [Abstract][Full Text] [Related]
4. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
5. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
6. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
[TBL] [Abstract][Full Text] [Related]
7. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
8. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
[No Abstract] [Full Text] [Related]
9. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
10. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
11. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
[TBL] [Abstract][Full Text] [Related]
12. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
13. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
14. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
15. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
16. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
Raghunathan R; Longstaff XR; Hughes EG; Li SJ; Sant VR; Tseng CH; Rao J; Wu JX; Yeh MW; Livhits MJ
Surgery; 2024 Jan; 175(1):221-227. PubMed ID: 37926582
[TBL] [Abstract][Full Text] [Related]
18. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
[TBL] [Abstract][Full Text] [Related]
20. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
Yang Z; Zhang T; Layfield L; Esebua M
J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
